HYMOVIS^® ONE is contraindicated in patients with known hypersensitivity (allergy) to hyaluronate preparations or gram-positive bacterial proteins. Do not administer

HYMOVIS^® ONE to patients with infections or skin diseases in the area of the injection site or joint. The safety and effectiveness of HYMOVIS^® ONE have not been established in

pregnant women, nursing mothers, or children, or for use in joints other than the knee, or for concomitant use with other intra-articular (IA) injections. The effectiveness of

repeat treatment cycles of HYMOVIS^® ONE has not been established. No serious adverse events or pseudoseptic reactions were reported in the HYMOVIS^® ONE clinical study.

The adverse events experienced and reported in the HYMOVIS^® ONE clinical study were joint swelling, metatarsalgia, neck pain, and headache.

Rx Only. See package insert for full prescribing information, including indications, contraindications, adverse events, warnings, precautions, and side effects.